Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Nov;25(8):1291-1310.
doi: 10.1007/s10198-023-01655-x. Epub 2024 Jan 23.

AOTMiT reimbursement recommendations compared to other HTA agencies

Aneta Mela  1 , Dorota Lis  2 , Elżbieta Rdzanek  3 , Janusz Jaroszyński  4 , Marzena Furtak-Niczyporuk  5 , Bartłomiej Drop  6 , Tomasz Blicharski  7 , Maciej Niewada  3
Affiliations
Comparative Study

AOTMiT reimbursement recommendations compared to other HTA agencies

Aneta Mela et al. Eur J Health Econ. 2024 Nov.

Erratum in

Abstract

Our objective was to compare AOTMiT (Polish: Agencja Oceny Technologii Medycznych i Taryfikacji) recommendations to other HTA (Health Technology Assessment) agencies for newly registered drugs and new registration indications issued by the European Medicines Agency between 2014 and 2019. The study aims to assess the consistency and justifications of AOTMiT recommendations compared to that of other HTA agencies in 11 countries. A total of 2496 reimbursement recommendations published by 12 HTA agencies for 464 medicinal products and 525 indications were analyzed. Our analysis confirmed that the Polish AOTMiT agency seems to bear the closest resemblance to the corresponding HTA agencies from Canada (CADTH) and New Zealand (PHARMAC), when it comes to the outcome of HTA recommendations (positive or negative). Poland had a general scheme for justifying recommendations, similar to that of Ireland-four aspects (i.e., clinical efficacy, safety profile, cost-effectiveness, and impact on the payer's budget) are important for Poland when formulating the final decision. Compared to other countries, Poland shows a noticeably different pattern of justifying reimbursement recommendations, as revealed primarily in terms of budget impact and somewhat less so for cost-effectiveness rationales.

Keywords: AHTAPol; AOTMiT; HTA agencies; Reimbursement recommendations.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Number of recommendations evaluated in 2014–2019 in relation to the number of agencies
Fig. 2
Fig. 2
Number of evaluated recommendations in 2014–2019 by agency per country
Fig. 3
Fig. 3
Percentage of quotations (references) by agency per country
Fig. 4
Fig. 4
Percentage of favorable and unfavorable appraisals (ratings) within positive and negative recommendations. Favorable—intense color; unfavorable—bright color
Fig. 5
Fig. 5
Percentage of quotations (references) by therapeutic area
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gozzo, L., Paterson, K., Wong, O., Megerlin, F., Geldmacher, J., Popoli, P., Jommi, C., Fricke, F.-U., De Solà-Morales, O., Kamae, I., Rasi, G., Drago, F.: Towards a European harmonization of health technology assessment recommendations executive paper of European regulatory conference focused on the EU commission proposal to harmonize HTA. Front. Drug. Saf. Regul. 2, 970661 (2022). 10.3389/fdsfr.2022.970661
    1. Jahnz-Różyk, K., Kawalec, P., Malinowski, K., Czok, K.: Drug policy in Poland. Value Health Reg Issues. 13, 23–26 (2017). 10.1016/j.vhri.2017.07.001 - PubMed
    1. Kawalec, P., Sagan, A., Stawowczyk, E., Kowalska-Bobko, I., Mokrzycka, A.: Implementation of the 2011 reimbursement Act in Poland: desired and undesired effects of the changes in reimbursement policy. Health Policy 120(4), 356–361 (2016). 10.1016/j.healthpol.2016.02.010 - PubMed
    1. Kolasa, K., Wasiak, R.: Health technology assessment in Poland and Scotland: comparison of process and decisions. Int. J. Technol. Assess. Health Care 28(1), 70–76 (2012). 10.1017/S0266462311000699 - PubMed
    1. Wüller, H., Sowada, C., Bochenek, T.: Comparison between processes of HTA, pharmaceutical pricing and reimbursement, and their transparency in Germany and Poland. Zeszyty Naukowe Ochrony Zdrowia, Zdrowie Publiczne I Zarządzanie 13(1), 102–108 (2015). 10.4467/20842627OZ.15.010.4123

Publication types

LinkOut - more resources